HUMANIGEN, INC.


Associated tags: Health, Biotechnology, COVID-19, Pharmaceutical, Clinical Trials, Pharmaceutical industry, Research, Patient

Humanigen Announces Release of Abstracts at ASH

Retrieved on: 
금요일, 11월 5, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, SHIELD, Society, Medication, GM, MD, Chemokine, Toxic shock syndrome, Graft-versus-host disease, MHRA, Knowledge, Granulocyte-macrophage colony-stimulating factor, ASH, Rheumatoid arthritis, Goal, COVID-19, Research, 2021 Essex County Council election, Forward-looking statement, Non-Hodgkin lymphoma, Judgement, Risk, Twitter, LinkedIn, GM-CSF, SEC, Mayo Clinic, Toxicity, Pneumonia, Nasdaq, Patient, United Kingdom, Conditional, Vaccine, Pharmaceutical industry, Risk management

Our plans include initiating the Phase 3 SHIELD study of lenzilumab in the first half of 2022 and we may be able to announce interim data at ASH 2022.

Key Points: 
  • Our plans include initiating the Phase 3 SHIELD study of lenzilumab in the first half of 2022 and we may be able to announce interim data at ASH 2022.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Conditional Marketing Authorization.
  • All statements other than statements of historical facts contained in this press release are forward-looking statements.

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

Retrieved on: 
화요일, 10월 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CBL, Twitter, Lymphatic system, Chemokine, Clinical trial, COVID-19, Inflammation, Health, Rheumatoid arthritis, Padrón, Blood, Incidence, Granulocyte-macrophage colony-stimulating factor, Warner Sallman, Judgement, National Health, RAS, Leukemia, Chronic myelomonocytic leukemia, Survival, Risk, GM-CSF, SAHMRI, Goal, III, Hypersensitivity, SEC, Medical Research Council, Government, Precision medicine, Medical Research Future Fund, Medicare, CEO, Nasdaq, Acute leukemia, Patient, Mutation, South Australian Health and Medical Research Institute, University, LinkedIn, Geography, Cancer, Hematology, Knowledge, NRAS, TET2, National Health and Medical Research Council, Azacitidine, Forward-looking statement, GM, Associate, KRAS, Progression-free survival, Pharmaceutical industry, Vaccine, Risk management, PREACH-M, Humanigen, Inc., SAHMRI, PREACH-M, HUMANIGEN, INC., SAHMRI

The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.

Key Points: 
  • The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.
  • Patients with RAS pathway mutations such as KRAS, NRAS, or CBL, will be enrolled in the lenzilumab and azacitidine arm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • A phase 1 study of lenzilumab, a humaneered recombinant anti-human granulocyte-macrophage colony- stimulating factor (anti-hGM-CSF) antibody, for chronic myelomonocytic leukemia (CMML).